Junshi Biotech announced that the first phase III clinical study of the company's products JS207 and JS007 for first-line treatment of advanced hepatocellular carcinoma with bitriplimab and bevacizumab has completed the first patient administration. This study is the first domestically registered clinical study of JS207, and it is planned to enroll 560 subjects.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.